EGFR and non-small cell lung carcinoma: It is worth mentioning that EGFR-tyrosine kinase inhibitors (EGFR-TKI) prolong progression-free survival in NSCLC patients, but many patients eventually develop disease progression due to TKI-acquired resistance [71].